As you will be aware The Department for Health & Social Care has asked NICE to conduct an appraisal of Cosibelimab within its marketing authorisation for treating advanced cutaneous squamous cell carcinoma [ID6663].
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early February 2027 when we will write to you about how you can get involved.